Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease

Autor: Mehmet Boyraz, Bumin Dündar, Ferhat Cekmez, Ozgur Pirgon, Nihal Hatipoglu
Rok vydání: 2015
Předmět:
Male
obesity
Pediatric Obesity
medicine.medical_specialty
Long term treatment
Adolescent
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Aspartate Aminotransferases
digestive system
Body Mass Index
Endocrinology
Insulin resistance
Non-alcoholic Fatty Liver Disease
Internal medicine
Fatty Acids
Omega-3
Nonalcoholic fatty liver disease
medicine
insulin sensitivity
Humans
Insulin
Child
Life Style
Ultrasonography
chemistry.chemical_classification
biology
business.industry
Alanine Transaminase
medicine.disease
Long-Term Care
digestive system diseases
n-3 polyunsaturated fatty acids
Diet
Treatment Outcome
chemistry
Alanine transaminase
Pediatrics
Perinatology and Child Health
Fatty Acids
Unsaturated
biology.protein
Original Article
Female
Insulin Resistance
business
Body mass index
Polyunsaturated fatty acid
Zdroj: Journal of Clinical Research in Pediatric Endocrinology
ISSN: 1308-5727
Popis: Objective: To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD). Methods: One hundred and eight obese (body mass index (BMI) >95th percentile for age and sex) adolescents with NAFLD were included in the study. Mean age of the subjects was 13.8±3.9 years (9-17 yrs). The diagnosis of NAFLD was based on the presence of liver steatosis with high transaminases. The subjects were randomly divided into two groups. Group 1 (PUFA group, n=52) received a 1000 mg dose of PUFA once daily for 12 months and lifestyle intervention. Group 2 (placebo group, n=56) received a recommended diet plus placebo and lifestyle intervention for 12 months. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) from fasting samples. Results: BMI, fasting insulin levels and HOMA-IR values in both groups decreased significantly at the end of the study. In group 1, 67.8% of the patients had a decrease from baseline in the prevalence of steatosis (p0.05). Conclusion: Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.
Databáze: OpenAIRE
Externí odkaz: